pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
sojournix PRESS RELEASE ARCHIVE
Dec 8, 2020
Sojournix Advances Phase 2 Clinical Trial of SJX‑653 for Menopausal Hot Flashes
Nov 17, 2020
Sojournix to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference
Sep 28, 2020
Sojournix Presents Data at NAMS Showing SJX-653 Exhibits Potent NK3 Antagonist Profile Across Nonclinical and Initial Clinical Studies in Men and Postmenopausal Women
Sep 21, 2020
Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology and Metabolism
Feb 24, 2020
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes
Feb 18, 2020
Sojournix to Present at Cowen 2020 Healthcare Conference
Nov 5, 2019
Sojournix to Present at Stifel 2019 Healthcare Conference
Oct 7, 2019
Sojournix CEO Speaks Today at LSX World Congress USA
Mar 23, 2019
Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study
Mar 5, 2019
Sojournix To Present At Cowen And Company 39th Annual Health Care Conference
Feb 13, 2019
Sojournix Announces Positive Top-Line Phase 1 Data Demonstrating Clinical Proof of Mechanism and Once-Daily (QD) Pharmacokinetics for SJX-653
Feb 4, 2019
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
Jan 3, 2019
Sojournix Completes $44 Million Series C Financing
